Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-30
SponsorYale University
About this trial
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range. Specifically, investigators will describe how drivers of gluconeogenesis and lipemia (specifically measured as visceral fat ratio, insulin resistance, and postprandial lipemia,) that contribute to cardiometabolic risk in T1D change over time.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18 to ≤30 years
Diagnosed T1D for at least 12 months and with BMI <25 kg/m2.
Disqualifiers
Current use of adjunctive diabetes medication or anti-obesity medication
Insulin dose <0.5 units/kg/day
Use of lipid lowering prescription medication other than statins or omega-3 products
Doesn't meet MRI safety criteria or having claustrophobia
Trial design
Treatments tested in this trial
- Hyperinsulinemic-euglycemic clamp
- High Fat Mixed Meal Tolerance Test
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Yale University
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov